Gemtuzumab ozogamicin (GO) is an immunoconjugate consisting of the cytotoxic drug calicheamicin linked to an anti-CD33 antibody. Walter and colleagues reported that CD33 expression and P-glycoprotein (P-gp) function predict clinical outcome in adults suffering from acute myeloid leukemia (AML) treated with GO. 1 However, in leukemic samples from children, P-gp expression is infrequent. In a study designed to detect the clinical efficacy of P-gp inhibition, in pediatric AML, only 7 out of 447 (1.7%) children included expressed P-gp. 2 Both CD33 expression and P-gp are involved in drug transport and determine the amount of calicheamicin that is available inside the leukemic cell to induce apoptosis. We hypothesized that in addition to the availability, the intrinsic calicheamicin sensitivity of leukemic cells might play a role in the clinical response to GO.
Therefore, we determined the in vitro sensitivity to unconjugated calicheamicin in 90 newly diagnosed and 32 (unpaired) relapsed pediatric AML samples using the 4 day MTT assay (concentration range 0.000004-0.4 mg/ml), as previously described in detail. 3 The LC50 value, the drug concentration at which 50% of the cells are killed by the drug, is used as a measure of sensitivity. In addition to calicheamicin, a subset of samples was also tested for in vitro sensitivity to etoposide, cytarabine, daunorubicin, idarubicin, mitoxantrone, 6-thioguanine and L-asparaginase.
The clinical characteristics of the AML samples are detailed in Table 1 . We observed a more than 100 000-fold difference in calicheamicin sensitivity between the most sensitive and the most resistant patient samples ( Figure 1 ). Newly diagnosed AML samples were significantly more sensitive to calicheamicin compared with relapsed AML samples (RR ¼ 0.68; median LC50: 0.023 vs 0.034 mg/ml; P ¼ 0.042), although these patients had not been treated with GO. Despite the large overlap in calicheamicin sensitivity, this significant difference was mainly caused by the lack of relapsed AML samples with relatively high sensitivity to calicheamicin. There was marked cross-resistance between calicheamicin and the anthracyclines idarubicin More research is necessary to elucidate the mechanisms underlying calicheamicin resistance. 4 For example, calicheamicin induces double-strand DNA breaks and an increased ability to repair these breaks might induce resistance to calicheamicin. Calicheamicin LC50 (µg/ml) Diagnosis Relapse P =0.04 Figure 1 Variation in in vitro sensitivity to calicheamicin. There was more than 100 000-fold difference in calicheamicin sensitivity between the most sensitive and the most resistant patient samples. Newly diagnosed AML samples were significantly more sensitive to calicheamicin compared with relapsed AML samples (RR ¼ 0.68, median LC50: 0.023 vs 0.034 mg/ml, P ¼ 0.04), although these patients had not been treated with calicheamicin. Each symbol represents one patient and the median is depicted by a horizontal line. Abbreviations: WBC, white blood cell count; FAB, French-AmericanBritish. The clinical characteristics of the 90 newly diagnosed and 32 relapsed acute myeloid leukemia samples included in this study.
Letters to the Editor
As we observed marked cross-resistance between calicheamicin and anthracyclines, combining these compounds may be less likely to result in increased clinical efficacy. Based on our in vitro data, we suggest combining GO with cytarabine and/or L-asparaginase. Currently, most trials combine GO with cytarabine and an anthracycline. No clinical trial is studying the combination of GO with cytarabine and L-asparaginase.
The interpatient differences in calicheamicin sensitivity are the largest differences in drug sensitivity we have ever observed in pediatric AML, suggesting that it is likely that primary calicheamicin resistance plays a role in the response to GO. This needs to be validated in future clinical trials in which in vitro and in vivo response to GO/calicheamicin can be compared. In conclusion, when analyzing resistance to GO, primary resistance to calicheamicin should be considered as an important mechanism.
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